Opened the debate
Rises to address the issue of access for patients to medicines and medical devices. Explains that when a medicine is approved, it goes through two processes: first with the MHRA for safety and efficacy, then NICE for cost-effectiveness. Argues that despite legal rights outlined in the NHS constitution, there are practical hurdles preventing full access, including postcode lottery issues due to formulary restrictions. Proposes solutions such as automatic inclusion of NICE-approved drugs on local health system formularies within 28 days, an innovation officer role, differential pricing for multi-indication approvals, and formal delivery mechanisms for managed access treatments.